CTMX · CytomX Therapeutics, Inc.

Summary

CytomX Therapeutics entered into an underwriting agreement on March 17, 2026, with Jefferies LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co., and closed on March 19, 2026, the offering of 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 per warrant, expecting net proceeds of approximately $234.4 million.

Key takeaways

• Underwriting agreement dated March 17, 2026, with Jefferies LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co. as representatives of several underwriters.
• Issued 45,990,567 shares of common stock, $0.00001 par value, at offering price of $5.30 per share.
• Issued pre-funded warrants to purchase 1,179,245 shares of common stock at $5.29999 per warrant.
• Underwriters granted 30-day option to purchase up to 7,075,471 additional shares of common stock at public offering price.
• Offering closed March 19, 2026; completed sale of firm shares and pre-funded warrants.
• Estimated net proceeds approximately $234.4 million after underwriting discounts, commissions, and estimated offering expenses.
• Intends to use net proceeds for continued development of Varseta-M and other pipeline programs, general corporate purposes, and working capital needs.